Immunovia’s Analytical Validation Study of PancreaSure Published in Diagnostics

Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the publication of its analytical validation study in Diagnostics, a peer‑reviewed medical journal.

The analytical validation of PancreaSure was published in the article “Analytical Validation of a Serum Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma” and confirms the PancreaSure test’s strong reliability and robustness, supporting its role in the early detection of pancreatic cancer.

“We are pleased to see our study featured in Diagnostics and appreciate the recognition it has received. Our rigorous analytical validation has provided assurance that PancreaSure test delivers precise, reliable results, which is essential for advancing early detection of pancreatic cancer,” said Dr Lisa Ford, Immunovia’s Clinical Laboratory Director.

Immunovia’s validation study for PancreaSure delivered excellent results in precision, sensitivity, stability, and robustness, measuring more than 23 key performance attributes according to Clinical and Laboratory Standards Institute (CLSI) guidelines.

Previously, the validation study earned a 2025 Distinguished Abstract Award, chosen as one of only 19 winners from over 800 abstracts at the 2025 Annual Meeting of the Academy of Diagnostics & Laboratory Medicine (ADLM).

Diagnostics is an international, peer-reviewed, open access journal on medical diagnosis, published online twice a month by MDPI.

For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com

Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit www.immunovia.com.